Amgen Raises Full-Year Outlook Following Strong Third-Quarter Results

Amgen reported third-quarter 2026 revenue of $10.37 billion and adjusted EPS of $6.45, exceeding analyst estimates of $10.07 billion and $5.79. Product sales rose 8%, with management citing volume growth across its core portfolio. Amgen raised its 2026 revenue outlook to $38.9 billion–$39.7 billion from $38.2 billion–$39.4 billion, and its adjusted EPS forecast to $22.90–$23.70 from $22.30–$23.50.